MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
ENDRA Life Sciences Interest Expense 2011-2026 | NDRA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 460 K | -21.5 K | -41.5 K | 8.84 K | -107 K | -48 K | 42.6 K | 72 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 460 K | -107 K | 45.7 K |
Quarterly Interest Expense ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42 K | 13.1 K | 24.4 K | - | 65.5 K | 1.7 K | -4.84 K | - | 28.2 K | - | - | - | - | - | - | - | -7.51 K | 1.09 K | -2.04 K | - | -2.62 K | 1.26 K | 6.62 K | - | -44.6 K | -9.2 K | -1.52 K | - | -25.5 K | -23.7 K | 12.3 K | - | 2.03 K | 374 K | 28.1 K | - | 373 K | 235 K | -6.02 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 374 K | -44.6 K | 43.2 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 117.17 | 1.83 % | $ 35.6 B |  USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.2 | -4.35 % | $ 9.73 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.67 | 3.86 % | $ 888 M | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.6 | 5.63 % | $ 426 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
NeoGenomics
NEO
|
296 K | $ 7.96 | 3.51 % | $ 1.02 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.43 | 4.38 % | $ 1.9 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.38 | 1.08 % | $ 649 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 177.66 | 1.14 % | $ 8.81 B | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.69 | 0.15 % | $ 279 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 497.88 | 0.88 % | $ 14.4 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 194.98 | 2.83 % | $ 139 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 1.37 | 1.11 % | $ 90.4 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 125.77 | 4.0 % | $ 20 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 511.92 | 3.14 % | $ 193 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.3 | 5.99 % | $ 463 M | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.71 | -0.74 % | $ 61.9 M |  Irlanda |
 |
Guardant Health
GH
|
-10.5 M | $ 81.33 | 3.47 % | $ 10.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.79 | 3.72 % | $ 90.5 K | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 50.08 | 4.52 % | $ 3 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.09 | -1.88 % | $ 4.8 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.56 | 0.88 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 110.47 | 3.43 % | $ 9.11 B | Irlanda |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.66 | 0.05 % | $ 2.68 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.01 | 1.18 % | $ 22 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 201.61 | 4.44 % | $ 19.8 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 119.02 | 1.6 % | $ 5.57 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 81.19 | 0.74 % | $ 5.48 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Waters Corporation
WAT
|
14.3 M | $ 322.55 | 0.75 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 191.19 | -0.17 % | $ 21.2 B | USA |